Moderators: Paul DiSilvestro, MD & Annie Ellis, Patient Advocate

Presentations:

• GOG 3026 A Phase II Trial of Letrozole + Ribociclib in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum: A GOG Foundation Study (Brian Slomovitz, MD)
• Now: Neoadjuvant Olaparib Window Trial in Patients with Newly Diagnosed BRCA Mutant Ovarian Cancer (Shannon Westin, MD. Late-breaking abstract)
• Mirvetuximab Soravtansine (MIRV) in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha (FRα) Expression: Evaluation of Sequence of Therapy on Anti-Tumor Activity in the SORAYA Study (Robert Coleman, MD)
• Clinical Trial Participation is Associated with Improved Overall Survival in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer (Molly Morton, MD)
• A Phase II Trial Evaluating Cisplatin and Gemcitabine Concurrent with Intensity-Modulated Radiation Therapy (IMRT) for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva: NRG Oncology Trial #279 (Neil Horowitz, MD)
• A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer (Linda Duska, MD)
• Evolution of peripheral and tumor immune parameters as biomarkers of differential sequencing of immune checkpoint blockade and chemoradiotherapy in locally advanced cervical cancer: An NRG Oncology/GOG Study (Dmitry Zamarin, MD)
• Assessment of gynecologic cancer clinical trials by a new measure of equitable access: restrictive comorbidity criteria (Ann Oluloro, MD)
• Distillation (Carol Aghajanian, MD)